News & Insights

Emergent Announces Additions to Leadership Team

Emergent is pleased to announce the addition of two senior leaders to its  CDMO and Quality & Compliance organizations.

READ MORE

The Path to Reemergence

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...

READ MORE

Arrival of the Groninger INTEGRA

With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...

READ MORE

Rockville, MD Expansion Progress

Our drug product manufacturing facility in Rockville, Maryland is undergoing an expansion that will soon house a...

READ MORE

Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...

READ MORE

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021  Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...

READ MORE

Bloomberg: The Way Ahead

Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health...

READ MORE

All Hands on Deck for Fill/Finish of Vaccines and Therapeutics

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...

READ MORE

EMERGENT IN THE NEWS: COVID-19 General Coverage

Read the latest news coverage of Emergent's insights and involvement in the fight against COVID-19. Last Updated: Thursday,...

READ MORE

Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines

Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...

READ MORE

Molecule to Market: Inside the Outsourcing Space

Emergent recently had the pleasure of participating in the Molecule to Market Podcast hosted by Ramen Sehgal from from ra...

READ MORE

Lyophilized products are on the rise: Here's what you need to know

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug...

READ MORE

Supporting the Production of Next-Gen Therapies

“The Vanrx SA25 Aseptic Filling Workcell is a state-of-the-art machine, providing our clients with a high level of sterility...

READ MORE

Genetic Vaccine Platforms Demonstrate Their Potential

In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine...

READ MORE

BioPharm Intl Regulatory Sourcebook: GMPs Guide COVID-19 Vaccine Manufacturing

Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...

READ MORE

Factoring Stability in the Biologic Drug Mix

Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in ...

READ MORE

Gene therapy solution: The value of a CDMO as your end-to-end partner

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past...

READ MORE

Strategizing for Rapid Changeovers in Biologics Manufacturing

Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions recently contributed to an editorial...

READ MORE

Preparing Pandemic Vaccine Capacity

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently contributed to an editorial in ...

READ MORE

COVID-19: 'Pandemic-ready' set-up placing Emergent apart in CDMO Space

In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent...

READ MORE

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
READ MORE

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

  • Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large...
READ MORE

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

  • Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing...
READ MORE

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
READ MORE

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

  • CDMO agreement for NanoFlu to support pathway to licensure
  • Expanded collaboration now includes NanoFlu and COVID-19 vaccine...
READ MORE

Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...

READ MORE

Novavax agreement for Experimental Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...

READ MORE
WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at cdmo[at]ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.